How Are Health Plans Impacting Drug Prices?

Pharmaceutical Executive September 29, 2025
Mike Hollan

Key Takeaways

The MFN order could alter pharmaceutical innovation by enforcing foreign price-based drug cost reductions in the U.S.
The biopharma industry, comprising investors and companies, may struggle with U.S. competitiveness and drug development due to the MFN order.
Regulatory concerns, including the MFN order and IRA, have shifted oncology R&D focus from small to large molecules.
Small molecules, easier and cheaper to produce, face disadvantages under current regulations, impacting their development and accessibility.

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.

Peter Rubin, executive director of No Patient Left Behind, spoke with Pharmaceutical Executive about President Trump’s Most-Favored Nation (MFN)...

Today's Sponsors